glp 1 psoriatic arthritis Big news from the research side of One Rheumatology. Our clinical trial found encouraging improvements in patients with obesity when Taltz® was paired with GLP-1 therapy. This The potential role of GLP-1

Patients report that this rebound period (typically 2-4 weeks post-discontinuation) feels more difficult than maintaining the original weight loss started during treatment

In the SURPASS 2 trial, Tirzepatide, at all doses (5mg, 10mg and 15mg) was more effective at lowering Hba1c and blood glucose levels compared to Semaglutide 1mg, aka Ozempic

If youre feeling unusually tired, dizzy, or dealing with a persistent headache on your GLP-1 journey, the culprit is often simpler than you think

70 Notably, when the morphology of exenatide-induced neurites was evaluated alongside neurites generated by exposure to retinoic acid (RA), a well-characterized promoter of neurite outgrowth known to induce nuclear factor erythroid-derived 2 (Nrf2) upregulation, the overall morphology was similar to that of RA neurites

FLNA attributes recent volume declines to the multi-year effect of inflationary price increases taken at the shelf

First, MBS remains the most cost-effective option for moderate-to-severe obesity